LCC15-MB: A vimentin-positive human breast cancer cell line from a femoral bone metastasis

E. W. Thompson, V. Sung, M. Lavigne, K. Baumann, N. Azumi, A. D. Aaron, R. Clarke

Research output: Contribution to journalArticlepeer-review

13 Scopus citations

Abstract

The LCC15-MB cell line was established from a femoral bone metastasis that arose in a 29-year-old woman initially diagnosed with an infiltrating ductal mammary adenocarcinoma. The tumor had a relatively high (8%) S-phase fraction and 1/23 positive lymph nodes (LN). Both the primary tumor and LN metastasis were positive for estrogen receptor (ER) and progesterone receptor (PgR), but lacked erbB2 expression. Approximately one year later, the patient presented with a 0.8 cm comedo-type intraductal mammary adenocarcinoma in the left breast that was negative for ER and PgR, but positive for erbB2. Thirty-five months after the initial diagnosis she was treated for acute skeletal metastasis, and stabilized with a hip replacement. At this time, tumor cells were removed from surplus involved bone, inoculated into cell culture, and developed into the LCC15-MB cell line. The bone metastasis was a poorly differentiated adenocarcinoma lacking ER, PgR, and erbB2, characteristics shared by the LCC15-MB cells, although ER can be re-expressed by treatment of the LCC15-MB cells for 5 days with 75 μM 5-aza-2'-deoxycytidine. The LCC15-MB cell line is tumorigenic when implanted subcutaneously in NCr nu/nu mice and produces long-bone metastases after intracardiac injection. Although the bone metastasis from which the LCC15-MB cell line was derived lacked vimentin (VIM) expression, the original primary tumor and lymph node metastasis were strongly VIM positive, as are LCC15-MB cells in vitro and in nude mice. The karyotype and isozyme profiles of LCC15-MB cells are consistent with its origin from a human female, with most chromosome counts in the hypertriploid range. Thirty-two marker chromosomes are present. These cells provide an in vitro/in vivo model in which to study the inter-relationships between ER, VIM, and bone metastasis in human breast cancer.

Original languageEnglish (US)
Pages (from-to)193-204
Number of pages12
JournalClinical and Experimental Metastasis
Volume17
Issue number3
DOIs
StatePublished - 1999
Externally publishedYes

Bibliographical note

Funding Information:
Parts of the work were supported by the NIH grant CA61344, the US Army Medical Research Acquisition Activity (USAMRAA) grant DAMD17-96-1-6134, and the SPORE in breast cancer NIH grant 2P50-CA58185-04. This work was also supported in part by the Lombardi Cancer Center Shared Resources for Macromolecular Synthesis & Sequencing, Tissue Culture, Animals, and Cytochemistry & Microscopy, U.S. PHS Grant 2P30-CA-51008. We gratefully acknowledge Dr. John Newby, Washington County Hospital, Hagerstown for providing original archival blocks, Bharati Hukku and Joeseph Kaplan from the Cell Research Laboratory, for performing the karyotype and isozyme analysis, Rob Radinsky, MD Anderson Cancer Center, for advice on the keratin primers, and Jim Voeller, Lombardi Cancer Center, for providing the keratin 18 primers.

Keywords

  • Bone metastasis
  • Cell line
  • Demethylation
  • Estrogen receptor
  • Human breast cancer
  • Vimentin

Fingerprint

Dive into the research topics of 'LCC15-MB: A vimentin-positive human breast cancer cell line from a femoral bone metastasis'. Together they form a unique fingerprint.

Cite this